维升药业-B(2561.HK)IPO火爆逾70倍超购:基石阵容豪华

格隆汇
Mar 20, 2025

维升药业股份有限公司(简称“维升药业”,代码02561)发行价格为每股68.80港币,基础融资规模1亿美元(含扩大发行规模15%),绿鞋规模1500万美元(基础发行规模的15%),将于3月21日正式上市。

据悉,招股期截止时,预计其公开发售部分获得近70倍超额认购,国际发售部分同时获得超额申购。维升药业此次IPO引入了5名基石投资者,包括安科生物、苏州工业园区产业投资基金、Vivo Capital、药明生物、Reynold Lemkins等。

维升药业此次IPO受到市场高度认可,其背后还有多重因素推动。首先,维升药业自身实力强劲,专注于内分泌疾病治疗领域,拥有强大的产品管线。其核心产品隆培促生长素的上市许可申请已获中国国家药品监督管理局受理,商业化在即,同时还拥有多款内分泌治疗领域的潜在FIC/BIC候选药物,具有广阔的市场前景。

近日,维升药业的大股东Ascendis Pharma在美上市的股票价格逆势创出年内新高。有市场人士分析指出,除了Ascendis最新一期业绩表现优异等因素外,获得多家大行提升目标价也是其市场关注度提升的原因之一。市场或憧憬于维升药业上市后,Ascendis隐含持股价值有机会得到重估。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10